Galena Biopharma (GALE) Misses Q3 EPS by 63c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Roth Trims PT on Galena (GALE) Following Q3 Results, Plans to Spin Commercial Assets
November 10, 2015 9:18 AM ESTRoth Capital is trimming its price target on Buy-rated Galena Biopharma (Nasdaq: GALE) from $8 to $6 following Q3 results and plans to spin its commercial business, as... More
Galena Biopharma (GALE) Announces Presentation of GALE-301, GALE-302 Data
November 9, 2015 7:06 AM ESTGalena Biopharma (NASDAQ: GALE) announced that data from the Company's GALE-301 and GALE-302 clinical programs were presented at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting in National Harbor, Maryland. The data presented was on the primary vaccine series (PVS) from a randomized Phase 1b trial with GALE-301 (E39) and GALE-302 (E39' variant of E39; previously named J65) that are folate binding protein-derived (FBP) peptides.
Poster #166 (abstract #156) entitled, "Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the... More
